ACHIEVE Trial: Spironolactone Success Despite Fails
- For individuals undergoing maintenance dialysis, cardiovascular complications remain a leading cause of illness and death.
- The ACHIEVE trial (NCT03020303), a rigorously designed, randomized, placebo-controlled study, sought to determine if spironolactone could offer a benefit.
- Participants were then randomly assigned to continue receiving 25mg of spironolactone each day, or to receive a placebo - an inactive substance designed to look identical to the...
The Potential of Spironolactone for Dialysis Patients: A Closer Look
Table of Contents
For individuals undergoing maintenance dialysis, cardiovascular complications remain a leading cause of illness and death. A key player in this risk is believed to be aldosterone, a hormone that can contribute to heart problems. Though, the question of whether medications that block aldosterone’s effects – specifically, mineralocorticoid receptor antagonists – could improve outcomes for dialysis patients has remained largely unanswered. Recent research sheds new light on this critical area.
The ACHIEVE Trial: Evaluating Spironolactone’s Impact
The ACHIEVE trial (NCT03020303), a rigorously designed, randomized, placebo-controlled study, sought to determine if spironolactone could offer a benefit. Researchers focused on patients already receiving maintenance dialysis and who had demonstrated their ability to tolerate a low dose of 25mg of spironolactone daily for at least seven weeks. This initial “run-in” period ensured that only those who could safely adhere to the medication were included in the main study.
Participants were then randomly assigned to continue receiving 25mg of spironolactone each day, or to receive a placebo – an inactive substance designed to look identical to the medication. This approach helps eliminate bias and provides a clearer picture of spironolactone’s true effects.
Key Outcomes Measured
The primary goal of the ACHIEVE trial was to assess whether spironolactone reduced the combined risk of cardiovascular death or hospitalization due to heart failure. Researchers also tracked a range of secondary outcomes, including:
- Cause-specific mortality (death from a specific cause)
- Hospitalization specifically for heart failure
- Overall (all-cause) mortality
- All-cause hospitalizations
- Incidence of severe hyperkalemia (dangerously high potassium levels)
To ensure accuracy, all deaths and hospitalizations related to heart failure were carefully reviewed and confirmed by autonomous adjudicators.
What This Means for Patients
the findings from the ACHIEVE trial, as of October 2, 2025, offer valuable insights for both patients and healthcare providers. While the full results are still being analyzed and disseminated, this research represents a notable step forward in understanding how to best manage cardiovascular risk in the dialysis population. Further discussion with your nephrologist is crucial to determine if spironolactone,or other mineralocorticoid receptor antagonists,are appropriate for your individual health needs and circumstances.
Critically important considerations
It’s important to note that spironolactone, like all medications, carries potential risks. The ACHIEVE trial also monitored for severe hyperkalemia, a possibly life-threatening condition where potassium levels become dangerously high. Careful monitoring of potassium levels is thus essential for any patient taking a mineralocorticoid receptor antagonist.